Navigation Links
Aton Pharma Appoints Dr. Wayne Mulcahy to Vice President, Clinical Operations
Date:2/16/2010

LAWRENCEVILLE, N.J., Feb. 16 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, announced today that Wayne S. Mulcahy, Ph.D., has joined the company as Vice President, Clinical Operations. A wholly owned subsidiary of Princeton Pharma Holdings LLC, Aton is focused on the development and commercialization of unique products in ophthalmology and orphan diseases.

The company's comprehensive portfolio of well-established specialty pharmaceuticals targets cardiovascular (Mephyton®, Edecrin®, Sodium Edecrin®), metabolic (Cuprimine®, Syprine®, Demser®) and ophthalmic (Lacrisert® and the Timoptic® product line) diseases.

With more than 30 years of experience in clinical operations, Dr. Mulcahy has been responsible for the development and management of clinical programs across a range of therapeutic classes, including cardiovascular and CNS disorders, experience which is highly relevant to the clinical programs he will lead for Aton.

"Dr. Mulcahy's extensive scientific, clinical and regulatory background will provide exemplary leadership for Aton's burgeoning pipeline of development programs," said Michael G. Wells, Chief Executive Officer of Aton Pharma. "His technical acumen and strong track record of NDA submissions will help Aton fulfill its mission of bringing innovative and medically necessary medications to patients in need around the world."

Prior to joining Aton, Dr. Mulcahy served as Vice President of Research and Development at Alita Pharmaceuticals, as Vice President of Clinical Operations at the Duramed Research subsidiary of Barr Pharmaceuticals and as Senior Director of Scientific and Regulatory Affairs at Teva Pharmaceuticals North America. He began his pharmaceutical career at Merck Research Laboratories where he was awarded a Doctoral Study Fellowship. Dr. Mulcahy earned his Ph.D. in pharmacology from Temple University School of Medicine, an M.S. from Drexel University and his B.A. from Arcadia University.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global, diversified specialty pharmaceutical company providing essential treatments for under-treated diseases. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of products, with sales in over 30 countries, focuses on ophthalmic diseases and orphan conditions. For more information, see www.atonrx.com.

SOURCE Aton Pharma, Inc.

RELATED LINKS
http://www.atonrx.com

'/>"/>

SOURCE Aton Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VPCI Pioneers Virtual GMP Consulting for FDA Pharmaceutical Manufacturers
2. International Merchant Advisors, Inc. Signs LOI to Invest in Pharmaceutical Chain
3. Albemarle(R) Announces Custom Manufacturing Alliance with PharmaCore(R)
4. Bioniche Pharma Acquires Seven New Products From GeneraMedix Inc.
5. International Merchant Advisors, Inc. Offers to Invest in Pharmaceutical Chain
6. Endo Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on February 22, 2010
7. Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results
8. PARI Pharma Enrolls First Patient in Phase 2b Study of L-CsA
9. Creative Alliances with Nontraditional Players Increasingly Essential for Survival in Pharmaceutical Industry, New Ernst & Young Report Finds
10. Berkery Noyes Releases 2009 Pharma and Healthcare Information Merger & Acquisition Trends
11. Expanded London Genetics Web Site Emphasises Importance of Pharmacogenetics in Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/7/2017)... --  Provista, a proven leader in the supply ... power, today announced a new resource area on Provistaco.com ... is the online home for case studies, articles on ... releases, slideshows and events. ... at their fingertips, viewers can also watch short videos ...
(Date:10/4/2017)... LAWRENCE, Mass. , Oct. 4, 2017 /PRNewswire/ ... developer of single-use, self-contained, illuminating medical devices, today ... National Health Surveillance Agency (or Agência Nacional ... ®. The first single-use, cordless surgical retractor with ... ONETRAC provides optimal access, illumination and exposure of ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Leading pediatric ... peers in Washington, D.C., for the 49th Congress of the International Society of ... Vice President of the Center for Cancer and Blood Disorders at Children’s ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy ... health literacy software tool, and the Cancer Patient Education Network (CPEN), an independent ... today announce a new strategic alliance. , As CPEN’s strategic partner, HLI ...
(Date:10/12/2017)... ... 12, 2017 , ... Farm Forward joins Bon ... leading institutions in announcing the launch of the Leadership Circle , a ... are raised for food. , Founding members of the Leadership Circle also include ...
Breaking Medicine News(10 mins):